Large-scale testing (Phase 3)Study completedNCT03268954
What this trial is testing
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Who this might be right for
Myelodysplastic SyndromeLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
Takeda 454